These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 38702859)

  • 1. Response to comments on 'sensitivity of estimands in clinical trials with imperfect compliance'.
    Chen H; Heitjan DF
    Int J Biostat; 2024 May; ():. PubMed ID: 38702859
    [No Abstract]   [Full Text] [Related]  

  • 2. Sensitivity of estimands in clinical trials with imperfect compliance.
    Chen H; Heitjan DF
    Int J Biostat; 2024 May; 20(1):57-67. PubMed ID: 37365674
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Estimands: discussion points from the PSI estimands and sensitivity expert group.
    Phillips A; Abellan-Andres J; Soren A; Bretz F; Fletcher C; France L; Garrett A; Harris R; Kjaer M; Keene O; Morgan D; O'Kelly M; Roger J
    Pharm Stat; 2017 Jan; 16(1):6-11. PubMed ID: 26997517
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Choosing estimands in clinical trials with missing data.
    Mallinckrodt C; Molenberghs G; Rathmann S
    Pharm Stat; 2017 Jan; 16(1):29-36. PubMed ID: 27492760
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Choosing Estimands in Clinical Trials: Putting the ICH E9(R1) Into Practice.
    Ratitch B; Bell J; Mallinckrodt C; Bartlett JW; Goel N; Molenberghs G; O'Kelly M; Singh P; Lipkovich I
    Ther Innov Regul Sci; 2020 Mar; 54(2):324-341. PubMed ID: 32072573
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Estimands for clinical endpoints in tuberculosis treatment randomized controlled trials: a retrospective application in a completed trial.
    Weir IR; Dufault SM; Phillips PPJ
    Trials; 2024 Mar; 25(1):180. PubMed ID: 38468320
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Estimands for clinical endpoints in Tuberculosis treatment randomized controlled trials: a retrospective application in a completed trial.
    Weir IR; Dufault SM; Phillips PP
    Res Sq; 2023 Nov; ():. PubMed ID: 37986887
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Estimation of treatment effects in short-term depression studies. An evaluation based on the ICH E9(R1) estimands framework.
    Mitroiu M; Teerenstra S; Oude Rengerink K; Pétavy F; Roes KCB
    Pharm Stat; 2022 Sep; 21(5):1037-1057. PubMed ID: 35678545
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comments on "A taxonomy of estimands for regulatory clinical trials with discontinuations".
    Doi M; Watanabe D; Takenouchi K; Tsuchikawa M
    Stat Med; 2017 Nov; 36(27):4414-4416. PubMed ID: 29110371
    [No Abstract]   [Full Text] [Related]  

  • 10. Time-to-event estimands and loss to follow-up in oncology in light of the estimands guidance.
    Siegel JM; Weber HJ; Englert S; Liu F; Casey M;
    Pharm Stat; 2024 Mar; ():. PubMed ID: 38553421
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Setting positive end-expiratory pressure: does the 'best compliance' concept really work?
    Menga LS; Subirà C; Wong A; Sousa M; Brochard LJ
    Curr Opin Crit Care; 2024 Feb; 30(1):20-27. PubMed ID: 38085857
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Author's reply to comments on "A taxonomy of estimands for regulatory clinical trials with discontinuations".
    Permutt T
    Stat Med; 2017 Nov; 36(27):4417. PubMed ID: 29110369
    [No Abstract]   [Full Text] [Related]  

  • 13. Starting a conversation about estimands with public partners involved in clinical trials: a co-developed tool.
    Cro S; Kahan BC; Patel A; Henley A; C J; Hellyer P; Kumar M; Rahman Y; Goulão B
    Trials; 2023 Jul; 24(1):443. PubMed ID: 37408080
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Defining Efficacy Estimands in Clinical Trials: Examples Illustrating ICH E9(R1) Guidelines.
    Ratitch B; Goel N; Mallinckrodt C; Bell J; Bartlett JW; Molenberghs G; Singh P; Lipkovich I; O'Kelly M
    Ther Innov Regul Sci; 2020 Mar; 54(2):370-384. PubMed ID: 32072586
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Defining estimands in clinical trials: A unified procedure.
    Han S; Zhou XH
    Stat Med; 2023 May; 42(12):1869-1887. PubMed ID: 36883638
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comments on 'Estimands in clinical trials - broadening the perspective'.
    Rockhold F
    Stat Med; 2017 Jan; 36(1):24-26. PubMed ID: 27917552
    [No Abstract]   [Full Text] [Related]  

  • 17. Comments on 'Estimands in clinical trials - broadening the perspective'.
    Bauer P
    Stat Med; 2017 Jan; 36(1):22-23. PubMed ID: 27917555
    [No Abstract]   [Full Text] [Related]  

  • 18. Comments on 'Estimands in clinical trials - broadening the perspective'.
    Permutt T
    Stat Med; 2017 Jan; 36(1):20-21. PubMed ID: 27917551
    [No Abstract]   [Full Text] [Related]  

  • 19. Incorporating and interpreting regulatory guidance on estimands in diabetes clinical trials: The PIONEER 1 randomized clinical trial as an example.
    Aroda VR; Saugstrup T; Buse JB; Donsmark M; Zacho J; Davies MJ
    Diabetes Obes Metab; 2019 Oct; 21(10):2203-2210. PubMed ID: 31168921
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A note on the draft International Council for Harmonisation guidance on estimands and sensitivity analysis.
    Mehrotra DV
    Clin Trials; 2019 Aug; 16(4):339-344. PubMed ID: 30977390
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.